
Gilberto Schwartsmann

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6152129/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet, The, 2016, 387, 545-557.	6.3	878
2	Natural products in anticancer therapy. Current Opinion in Pharmacology, 2001, 1, 364-369.	1.7	477
3	Planning cancer control in Latin America and the Caribbean. Lancet Oncology, The, 2013, 14, 391-436.	5.1	394
4	Marine organisms as a source of new anticancer agents. Lancet Oncology, The, 2001, 2, 221-225.	5.1	200
5	Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy. Annals of Oncology, 2007, 18, 1457-1466.	0.6	187
6	Antiâ€Cancer Drug Discovery and Development in Brazil: Targeted Plant Collection as a Rational Strategy to Acquire Candidate Antiâ€Cancer Compounds. Oncologist, 2000, 5, 185-198.	1.9	175
7	A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Annals of Oncology, 2008, 19, 1547-1552.	0.6	167
8	Targeting Protein Kinase C: New Therapeutic Opportunities Against Highâ€Grade Malignant Gliomas?. Oncologist, 2002, 7, 17-33.	1.9	141
9	Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas. World Neurosurgery, 2008, 70, 259-266.	1.3	113
10	EO9: A novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models. European Journal of Cancer, 1993, 29, 897-906.	1.3	112
11	A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer. Investigational New Drugs, 2000, 18, 83-91.	1.2	103
12	Evidence for an association of human papillomavirus infection and colorectal cancer. European Journal of Surgical Oncology, 2007, 33, 569-574.	0.5	101
13	Altered extracellular ATP, ADP and AMP catabolism in glioma cell lines. Cancer Letters, 2003, 198, 211-218.	3.2	95
14	Sequence-dependent growth inhibition and DNA damage formation by the irinotecan–5-fluorouracil combination in human colon carcinoma cell lines. European Journal of Cancer, 1999, 35, 1851-1861.	1.3	86
15	Marine-derived anticancer agents in clinical trials. Expert Opinion on Investigational Drugs, 2003, 12, 1367-1383.	1.9	82
16	Phase II Trial of Cisplatin Plus Decitabine, a New DNA Hypomethylating Agent, in Patients With Advanced Squamous Cell Carcinoma of the Cervix. American Journal of Clinical Oncology: Cancer Clinical Trials, 2002, 25, 496-501.	0.6	81
17	Essential drugs for cancer therapy: A World Health Organization consultation. Annals of Oncology, 1999, 10, 385-390.	0.6	79
18	Gastrin-Releasing Peptide Receptor as a Molecular Target for Psychiatric and Neurological Disorders. CNS and Neurological Disorders - Drug Targets, 2006, 5, 197-204.	0.8	79

#	Article	IF	CITATIONS
19	Extracellular nucleotides and nucleosides induce proliferation and increase nucleoside transport in human glioma cell lines. Journal of Neuro-Oncology, 2003, 64, 211-218.	1.4	72
20	Overview of Breast Health Care Guidelines for Countries with Limited Resources. Breast Journal, 2003, 9, S42-S50.	0.4	72
21	Cancer Chemotherapy and Cognitive Function in Rodent Models: Memory Impairment Induced by Cyclophosphamide in Mice. Clinical Cancer Research, 2006, 12, 5000-5001.	3.2	72
22	A phase I trial of the bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC3095 in patients with advanced solid malignancies. Investigational New Drugs, 2006, 24, 403-412.	1.2	69
23	Molecular mechanisms mediating gastrin-releasing peptide receptor modulation of memory consolidation in the hippocampus. Neuropharmacology, 2006, 51, 350-357.	2.0	68
24	Anticancer, antichemotactic and antimicrobial activities of marine sponges collected off the coast of Santa Catarina, southern Brazil. Journal of Experimental Marine Biology and Ecology, 2002, 281, 1-12.	0.7	63
25	Gastrin-releasing peptide receptor (GRPR) mediates chemotaxis in neutrophils. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 547-552.	3.3	61
26	Bombesin/gastrin-releasing peptide receptors in the basolateral amygdala regulate memory consolidation. European Journal of Neuroscience, 2004, 19, 1041-1045.	1.2	59
27	Serum Hsp70 as an Early Predictor of Fatal Outcome after Severe Traumatic Brain Injury in Males. Journal of Neurotrauma, 2005, 22, 966-977.	1.7	59
28	Treatment of Breast Cancer in Countries with Limited Resources. Breast Journal, 2003, 9, S67-S74.	0.4	58
29	Gastrin-releasing Peptide Receptor Antagonist Effects on an Animal Model of Sepsis. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 84-90.	2.5	57
30	Lymph Node Retrieval after Preoperative Chemoradiotherapy for Rectal Cancer. Journal of Gastrointestinal Surgery, 2012, 16, 1573-1580.	0.9	55
31	PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines. Investigational New Drugs, 2014, 32, 783-794.	1.2	55
32	Mangiferin, a naturally occurring glucoxilxanthone improves long-term object recognition memory in rats. European Journal of Pharmacology, 2010, 635, 124-128.	1.7	54
33	Systemic treatment of AIDS-related Kaposi sarcoma: Current status and perspectives. Cancer Treatment Reviews, 2006, 32, 445-455.	3.4	52
34	Marine organisms and other novel natural sources of new cancer drugs. Annals of Oncology, 2000, 11, 235-244.	0.6	51
35	Sentinel lymph node in carcinoma of the anal canal: A review. European Journal of Surgical Oncology, 2006, 32, 247-252.	0.5	51
36	BDNF/TrkB Content and Interaction with Gastrin-Releasing Peptide Receptor Blockade in Colorectal Cancer. Oncology, 2010, 79, 430-439.	0.9	50

#	Article	IF	CITATIONS
37	Ultra-high performance liquid chromatography tandem mass spectrometric method for the determination of tamoxifen, N -desmethyltamoxifen, 4-hydroxytamoxifen and endoxifen in dried blood spots—Development, validation and clinical application during breast cancer adjuvant therapy. Talanta, 2015, 132, 775-784.	2.9	50
38	Gastrin-releasing peptide receptors in the central nervous system: role in brain function and as a drug target. Frontiers in Endocrinology, 2012, 3, 159.	1.5	49
39	The Histone Deacetylase Inhibitor Sodium Butyrate Promotes Cell Death and Differentiation and Reduces Neurosphere Formation in Human Medulloblastoma Cells. Molecular Neurobiology, 2013, 48, 533-543.	1.9	48
40	Gastrin-Releasing Peptide Receptor Expression in Lung Cancer. Archives of Pathology and Laboratory Medicine, 2014, 138, 98-104.	1.2	48
41	Systemic administration of doxorubicin impairs aversively motivated memory in rats. Pharmacology Biochemistry and Behavior, 2009, 94, 239-243.	1.3	47
42	International Scientific Collaboration in HIV and HPV: A Network Analysis. PLoS ONE, 2014, 9, e93376.	1.1	46
43	Intrahippocampal infusion of the bombesin/gastrin-releasing peptide antagonist RC-3095 impairs inhibitory avoidance retention. Peptides, 2003, 24, 1069-1074.	1.2	45
44	BDNF/TrkB signaling protects HT-29 human colon cancer cells from EGFR inhibition. Biochemical and Biophysical Research Communications, 2012, 425, 328-332.	1.0	41
45	Phase I study of Brequinar sodium (NSC 368390) in patients with solid malignancies. Cancer Chemotherapy and Pharmacology, 1990, 25, 345-351.	1.1	40
46	Phase II study of thalidomide in patients with metastatic malignant melanoma. Melanoma Research, 2004, 14, 527-531.	0.6	40
47	Glioma Revisited: From Neurogenesis and Cancer Stem Cells to the Epigenetic Regulation of the Niche. Journal of Oncology, 2012, 2012, 1-20.	0.6	40
48	Breast cancer in Latin America. Cancer, 2008, 113, 2359-2365.	2.0	36
49	Screening for antiproliferative activity of six southern Brazilian species of Hypericum. Phytomedicine, 2005, 12, 112-115.	2.3	35
50	Von Willebrand factor in colorectal cancer. International Journal of Colorectal Disease, 2002, 17, 42-45.	1.0	34
51	Hsp70 response to 5-fluorouracil treatment in human colon cancer cell lines. International Journal of Colorectal Disease, 2007, 22, 1201-1208.	1.0	34
52	Anti-proliferative effect of the gastrin-release peptide receptor antagonist RC-3095 plus temozolomide in experimental glioblastoma models. Journal of Neuro-Oncology, 2009, 93, 191-201.	1.4	34
53	BDNF and PDE4, but not the GRPR, Regulate Viability of Human Medulloblastoma Cells. Journal of Molecular Neuroscience, 2010, 40, 303-310.	1.1	34
54	Gastrin-releasing peptide receptor content in human glioma and normal brain. Brain Research Bulletin, 2010, 82, 95-98.	1.4	34

#	Article	IF	CITATIONS
55	Anticancer drug screening and discovery in the 1990s: a European perspective. European Journal of Cancer, 1993, 29, 3-14.	1.3	33
56	Opposite effects of low and high doses of the gastrin-releasing peptide receptor antagonist RC-3095 on memory consolidation in the hippocampus: Possible involvement of the GABAergic system. Peptides, 2006, 27, 2307-2312.	1.2	33
57	Stimulation of Proliferation of U138-MG Glioblastoma Cells by Gastrin-Releasing Peptide in Combination with Agents That Enhance cAMP Signaling. Oncology, 2008, 75, 27-31.	0.9	33
58	Analysis of KIR gene frequencies and HLA class I genotypes in breast cancer and control group. Human Immunology, 2013, 74, 1130-1133.	1.2	33
59	Health-related quality of life before and during chemotherapy in patients with early-stage breast cancer. Ecancermedicalscience, 2020, 14, 1007.	0.6	33
60	DUP 785 (NSC 368390): Schedule-dependency of growth-inhibitory and antipyrimidine effects. Biochemical Pharmacology, 1988, 37, 3257-3266.	2.0	32
61	A study of the delivery-targeting concept applied to antineoplasic drugs active on human osteosarcoma. I. Synthesis and biological activity in nude mice carrying human osteosarcoma xenografts of gem-bisphosphonic methotrexate analogues. European Journal of Medicinal Chemistry, 1992. 27. 825-833.	2.6	32
62	Comparative genotoxic effect of vincristine, vinblastine, and vinorelbine in somatic cells of Drosophila melanogaster. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2002, 519, 141-149.	0.9	32
63	RC-3095, a bombesin/gastrin-releasing peptide receptor antagonist, impairs aversive but not recognition memory in rats. European Journal of Pharmacology, 2004, 486, 35-41.	1.7	32
64	Impairments of social behavior and memory after neonatal gastrin-releasing peptide receptor blockade in rats: Implications for an animal model of neurodevelopmental disorders. Neuropharmacology, 2007, 52, 724-732.	2.0	32
65	BDNF/TrkB signaling as an anti-tumor target. Expert Review of Anticancer Therapy, 2011, 11, 1473-1475.	1.1	32
66	Sentinel Lymph Node Procedure in Patients With Epidermoid Carcinoma of the Anal Canal. Diseases of the Colon and Rectum, 2003, 46, 1032-1037.	0.7	31
67	Current and emerging molecular targets in glioma. Expert Review of Anticancer Therapy, 2010, 10, 1735-1751.	1.1	31
68	Title is missing!. Annals of Oncology, 2000, 11, 235-244.	0.6	31
69	Pharmacokinetic and Pharmacogenetic Markers of Irinotecan Toxicity. Current Medicinal Chemistry, 2019, 26, 2085-2107.	1.2	31
70	Gastrin-Releasing Peptide Receptors Regulate Proliferation of C6 Glioma Cells through a Phosphatidylinositol 3-Kinase-Dependent Mechanism. Current Neurovascular Research, 2008, 5, 99-105.	0.4	30
71	Protective effect of RC-3095, an antagonist of the gastrin-releasing peptide receptor, in experimental arthritis. Arthritis and Rheumatism, 2011, 63, 2956-2965.	6.7	30
72	Gastrin-releasing peptide receptor signaling in the integration of stress and memory. Neurobiology of Learning and Memory, 2014, 112, 44-52.	1.0	30

#	Article	IF	CITATIONS
73	Phase II Study of Pentosan Polysulfate (PPS) in Patients with AIDS-related Kaposi's Sarcoma. Tumori, 1996, 82, 360-363.	0.6	29
74	The main steps in the development of anticancer agents. Radiotherapy and Oncology, 1988, 12, 301-313.	0.3	28
75	EORTC new drug development office coordinating and monitoring programme for phase I and II trials with new anticancer agents. European Journal of Cancer & Clinical Oncology, 1991, 27, 1162-1168.	0.9	27
76	The Irinotecan/5-Fluorouracil Combination Induces Apoptosis and Enhances Manganese Superoxide Dismutase Activity in HT-29 Human Colon Carcinoma Cells. Chemotherapy, 2005, 51, 93-102.	0.8	27
77	The Effects of Sample Size on the Outcome of Ovarian Tissue Cryopreservation. Reproduction in Domestic Animals, 2010, 45, 99-102.	0.6	27
78	Anti-tumour Screening of Brazilian Plants. Pharmaceutical Biology, 2002, 40, 603-616.	1.3	26
79	Histone deacetylase inhibitors: A new perspective for the treatment of leukemia. Leukemia Research, 2010, 34, 687-695.	0.4	26
80	Gastrin-Releasing Peptide as a Molecular Target for Inflammatory Diseases: An Update. Inflammation and Allergy: Drug Targets, 2013, 12, 172-177.	1.8	26
81	Radioresistance is associated to increased Hsp70 content in human glioblastoma cell lines. International Journal of Oncology, 2004, 25, 777.	1.4	25
82	The bombesin/gastrin releasing peptide receptor antagonist RC-3095 blocks apomorphine but not MK-801-induced stereotypy in mice. Peptides, 2004, 25, 585-588.	1.2	25
83	Low cytotoxicity of ecteinascidin 743 in yeast lacking the major endonucleolytic enzymes of base and nucleotide excision repair pathways. Biochemical Pharmacology, 2005, 70, 59-69.	2.0	25
84	Irinotecan/5-Fluorouracil Combination Induces Alterations in Mitochondrial Membrane Potential and Caspases on Colon Cancer Cell Lines. Oncology Research, 2005, 15, 385-392.	0.6	25
85	A study of the killer cell immunoglobulinâ€like receptor gene KIR2DS1 in a Caucasoid Brazilian population with psoriasis vulgaris. Tissue Antigens, 2008, 72, 392-396.	1.0	25
86	Effects of N-Acetylcysteine/Deferoxamine, Taurine and RC-3095 on Respiratory Chain Complexes and Creatine Kinase Activities in Rat Brain After Sepsis. Neurochemical Research, 2010, 35, 515-521.	1.6	25
87	Bombesin receptor regulation of emotional memory. Reviews in the Neurosciences, 2012, 23, 571-86.	1.4	25
88	Phase II study of teniposide in patients with AIDS-related Kaposi's sarcoma. European Journal of Cancer & Clinical Oncology, 1991, 27, 1637-1639.	0.9	24
89	Carcinomatous meningitis as a clinical manifestation of pancreatic carcinoma. Annals of Oncology, 2001, 12, 1757-1759.	0.6	24
90	Epidemiologic correlates of antibody response to human papillomavirus among women at low risk of cervical cancer. International Journal of STD and AIDS, 2003, 14, 258-265.	0.5	24

#	Article	IF	CITATIONS
91	Neuropeptides and anxiety disorders: bombesin receptors as novel therapeutic targets. Trends in Pharmacological Sciences, 2004, 25, 241-242.	4.0	24
92	Antitumor activity of three benzopyrans isolated from Hypericum polyanthemum. Fìtoterapìâ, 2005, 76, 210-215.	1.1	24
93	Sodium butyrate enhances the cytotoxic effect of antineoplastic drugs in human lymphoblastic T-cells. Leukemia Research, 2009, 33, 218-221.	0.4	24
94	<i>CYP3A4*22</i> is related to increased plasma levels of 4-hydroxytamoxifen and partially compensates for reduced CYP2D6 activation of tamoxifen. Pharmacogenomics, 2015, 16, 601-617.	0.6	24
95	Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial. European Journal of Cancer, 2018, 105, 71-78.	1.3	24
96	Differences in Breast Cancer Stage at Diagnosis by Ethnicity, Insurance Status, and Family Income in Young Women in the USA. Journal of Racial and Ethnic Health Disparities, 2019, 6, 909-916.	1.8	24
97	A role for hippocampal gastrin-releasing peptide receptors in extinction of aversive memory. NeuroReport, 2006, 17, 935-939.	0.6	23
98	Gastrin-Releasing Peptide Receptor Expression in Cervical Cancer. Oncology, 2007, 73, 340-345.	0.9	23
99	Tamoxifen inhibits particulate-associated protein kinase C activity, and sensitises cultured human glioblastoma cells not to etoposide but to γ-radiation and BCNU. European Journal of Cancer, 1999, 35, 833-839.	1.3	22
100	Dexamethasone reverses the memory impairment induced by antagonism of hippocampal gastrin-releasing peptide receptors. Peptides, 2005, 26, 821-825.	1.2	22
101	Gastrin-Releasing Peptide Receptor as a Molecular Target for Inflammatory Diseases. Inflammation and Allergy: Drug Targets, 2007, 6, 197-200.	1.8	22
102	Study of killer immunoglobulin-like receptor genes and human leukocyte antigens class I ligands in a Caucasian Brazilian population with Crohn's disease and ulcerative colitis. Human Immunology, 2010, 71, 293-297.	1.2	22
103	Endogenous plasma and salivary uracil to dihydrouracil ratios and DPYD genotyping as predictors of severe fluoropyrimidine toxicity in patients with gastrointestinal malignancies. Clinical Biochemistry, 2016, 49, 1221-1226.	0.8	22
104	Long-term behavioral effects of neonatal blockade of gastrin-releasing peptide receptors in rats: Similarities to autism spectrum disorders. Behavioural Brain Research, 2014, 263, 60-69.	1.2	21
105	Influence of CYP2D6 and CYP3A4 Phenotypes, Drug Interactions, and Vitamin D Status on Tamoxifen Biotransformation. Therapeutic Drug Monitoring, 2015, 37, 733-744.	1.0	21
106	Determination of irinotecan and its metabolite SN-38 in dried blood spots using high-performance liquid-chromatography with fluorescence detection. Journal of Pharmaceutical and Biomedical Analysis, 2018, 150, 51-58.	1.4	21
107	Multidrug resistance gene expression during the murine ontogeny. Mechanisms of Ageing and Development, 2001, 122, 255-270.	2.2	20
108	In vitro Cytotoxicity of Extracts from Brazilian Asteraceae. Pharmaceutical Biology, 2002, 40, 494-500.	1.3	20

#	Article	IF	CITATIONS
109	Non-associative learning and anxiety in rats treated with a single systemic administration of the gastrin-releasing peptide receptor antagonist RC-3095. Peptides, 2005, 26, 2525-2529.	1.2	20
110	Effects of an antagonist of the bombesin/gastrin-releasing peptide receptor on complete Freund's adjuvant-induced arthritis in rats. Peptides, 2008, 29, 1726-1731.	1.2	20
111	Musical hallucinations following insular glioma resection. Neurosurgical Focus, 2010, 28, E9.	1.0	20
112	Association of killer cell immunoglobulin-like receptors and human leukocyte antigen–C genotypes in South Brazilian with type 1 diabetes. Human Immunology, 2010, 71, 799-803.	1.2	20
113	Economic evaluation of strategies for managing women with equivocal cytological results in Brazil. International Journal of Cancer, 2011, 129, 671-679.	2.3	20
114	The anticancer estrogen receptor antagonist tamoxifen impairs consolidation of inhibitory avoidance memory through estrogen receptor alpha. Journal of Neural Transmission, 2017, 124, 1331-1339.	1.4	20
115	Protein Kinase C-Mediated in vitro Invasion of Human Glioma Cells through Extracellular-Signal-Regulated Kinase and Ornithine Decarboxylase. Pathobiology, 2000, 68, 113-123.	1.9	19
116	Phase II trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer. Investigational New Drugs, 2003, 21, 359-366.	1.2	19
117	Cancer Stem Cells and the Biology of Brain Tumors. Current Stem Cell Research and Therapy, 2009, 4, 306-313.	0.6	19
118	Phosphoinositide 3-kinase is required for bombesin-induced enhancement of fear memory consolidation in the hippocampus. Peptides, 2009, 30, 1192-1196.	1.2	19
119	Comparative antitumour activity of vinblastine-isoleucinate and related vinca alkaloids in human tumour xenografts. European Journal of Cancer, 1992, 28, 767-773.	1.3	18
120	Modulation of oxidative stress in response to gamma-radiation in human glioma cell lines. Journal of Neuro-Oncology, 2003, 61, 89-94.	1.4	18
121	Disparities in Cancer Care: A Worldwide Perspective and Roadmap for Change. Journal of Clinical Oncology, 2006, 24, 2135-2136.	0.8	18
122	A gastrin-releasing peptide receptor antagonist blocks d-amphetamine-induced hyperlocomotion and increases hippocampal NGF and BDNF levels in rats. Peptides, 2007, 28, 1447-1452.	1.2	18
123	The histone deacetylase inhibitor sodium butyrate in combination with brain-derived neurotrophic factor reduces the viability of DAOY human medulloblastoma cells. Child's Nervous System, 2011, 27, 897-901.	0.6	18
124	Targeting tyrosine receptor kinase B in gliomas. Neuro-Oncology, 2017, 19, 138-139.	0.6	18
125	Tropomyosin-Related Kinase Receptor and Neurotrophin Expression in Cutaneous Melanoma Is Associated with a Poor Prognosis and Decreased Survival. Oncology, 2019, 97, 26-37.	0.9	18
126	High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Rescue in a Patient With Pleuropulmonary Blastoma. Journal of Pediatric Hematology/Oncology, 2003, 25, 78-81.	0.3	17

#	Article	IF	CITATIONS
127	MAPK pathway activation in colorectal cancer: a therapeutic opportunity for GRP receptor antagonists. Lancet Oncology, The, 2005, 6, 444-445.	5.1	17
128	HER2 as a cancer stem-cell target. Lancet Oncology, The, 2010, 11, 225-226.	5.1	17
129	DPD functional tests in plasma, fresh saliva and dried saliva samples as predictors of 5-fluorouracil exposure and occurrence of drug-related severe toxicity. Clinical Biochemistry, 2018, 56, 18-25.	0.8	17
130	Reversal by Interleukin-2 of Alopecia Universalis, Mucocutaneous Candidiasis, and Sexual Impotence in a Patient With Malignant Thymoma. Journal of the National Cancer Institute, 1993, 85, 673-673.	3.0	16
131	Fractionated Doses of Oral Etoposide in the Treatment of Patients With AIDS-Related Kaposi Sarcoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2001, 24, 177-184.	0.6	16
132	Analytical and clinical validation of a dried blood spot assay for the determination of paclitaxel using high-performance liquid chromatography-tandem mass spectrometry. Clinical Biochemistry, 2018, 54, 123-130.	0.8	16
133	Expanded analyses of napoli-1: Phase 3 study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy Journal of Clinical Oncology, 2015, 33, 234-234.	0.8	16
134	Growth inhibitory effects of 5-aza-2′-deoxycytidine in HL-60 promyelocytic leukemia cells resistant to differentiation induction. Biochemical and Biophysical Research Communications, 1986, 141, 629-635.	1.0	15
135	Sentinel lymph node identification and sampling in women with early breast cancer using 99mTc labelled dextran 500 and patent blue V dye. Nuclear Medicine Communications, 2001, 22, 1109-1117.	0.5	15
136	Metastatic renal cell carcinoma involving the rectum. International Journal of Colorectal Disease, 2002, 17, 359-361.	1.0	15
137	Breast cancer in Latin America: Experts perceptions compared with medical care standards. Breast, 2010, 19, 50-54.	0.9	15
138	Pharmacokinetics of Brequinar sodium (NSC 368390) in patients with solid tumors during a phase I study. European Journal of Cancer & Clinical Oncology, 1989, 25, 1675-1681.	0.9	14
139	Cancer research campaign operation manual for control recommendations for products derived from recombinant DNA technology prepared for investigational administration to patients with cancer in phase I trials. European Journal of Cancer, 1993, 29, 1907-1910.	1.3	14
140	Transient Disruption of Fear-Related Memory by Post-Retrieval Inactivation of Gastrin-Releasing Peptide or N-Methyl-D-Aspartate Receptors in the Hippocampus. Current Neurovascular Research, 2008, 5, 21-27.	0.4	14
141	A phosphodiesterase 4-controlled switch between memory extinction and strengthening in the hippocampus. Frontiers in Behavioral Neuroscience, 2014, 8, 91.	1.0	14
142	Inhibitory Activities of Trichostatin A in U87 Glioblastoma Cells and Tumorsphere-Derived Cells. Journal of Molecular Neuroscience, 2014, 54, 27-40.	1.1	14
143	Tumor Size as a Surrogate End Point for the Detection of Early Breast Cancer: A 30-Year (1972?2002), Single-Center Experience in Southern Brazil. Breast Journal, 2007, 13, 448-456.	0.4	13
144	A gastrinâ€releasing peptide receptor antagonist stimulates Neuro2a neuroblastoma cell growth: Prevention by a histone deacetylase inhibitor. Cell Biology International, 2009, 33, 899-903.	1.4	13

#	Article	IF	CITATIONS
145	Antiproliferative activity of the dimeric phloroglucinol and benzophenone derivatives of Hypericum spp. native to southern Brazil. Anti-Cancer Drugs, 2013, 24, 699-703.	0.7	13
146	Influence of GRPR and BDNF/TrkB signaling on the viability of breast and gynecologic cancer cells. Molecular and Clinical Oncology, 2013, 1, 148-152.	0.4	13
147	Administration of a Histone Deacetylase Inhibitor into the Basolateral Amygdala Enhances Memory Consolidation, Delays Extinction, and Increases Hippocampal BDNF Levels. Frontiers in Pharmacology, 2017, 8, 415.	1.6	13
148	Protective effect of gastrin-releasing peptide receptor antagonist in carrageenan-induced pleural inflammation in rats. Inflammation Research, 2010, 59, 783-789.	1.6	12
149	Gastrin-Releasing Peptide Receptor Antagonism Induces Protection from Lethal Sepsis: Involvement of Toll-like Receptor 4 Signaling. Molecular Medicine, 2012, 18, 1209-1219.	1.9	12
150	Emerging Therapeutic Agents for Cervical Cancer. Recent Patents on Anti-Cancer Drug Discovery, 2009, 4, 196-206.	0.8	12
151	A progress report of a phase I study of interferon-gamma and interleukin-2 and some comments on the mechanism of the toxicity due to interleukin-2. Cancer Treatment Reviews, 1989, 16, 105-109.	3.4	11
152	Phase II trial of paclitaxel and ifosfamide as a salvage treatment in metastatic breast cancer. Breast Cancer Research and Treatment, 1997, 45, 47-53.	1.1	11
153	Gemcitabine administered as a short infusion versus a fixed dose rate in combination with cisplatin for the treatment of patients with advanced non-small cell lung cancer. Lung Cancer, 2007, 58, 80-87.	0.9	11
154	Effects of an Antagonist of the Gastrin-Releasing Peptide Receptor in an Animal Model of Uveitis. , 2009, 50, 5300.		11
155	Analysis of KIR gene frequencies and HLA class I genotypes in prostate cancer and control group. International Journal of Immunogenetics, 2012, 39, 423-428.	0.8	11
156	Improved determination of uracil and dihydrouracil in plasma after a loading oral dose of uracil using high-performance liquid chromatography with photodiode array detection and porous graphitic carbon stationary phase. Clinical Biochemistry, 2015, 48, 915-918.	0.8	11
157	KIR genes and HLA class I ligands in a Caucasian Brazilian population with colorectal cancer. Human Immunology, 2017, 78, 263-268.	1.2	11
158	Combined Inhibition of HDAC and EGFR Reduces Viability and Proliferation and Enhances STAT3 mRNA Expression in Glioblastoma Cells. Journal of Molecular Neuroscience, 2019, 68, 49-57.	1.1	11
159	Effect of a gastrin-releasing peptide receptor antagonist and a proton pump inhibitor association in an animal model of gastritis. Peptides, 2009, 30, 1460-1465.	1.2	10
160	Influence of Purple Grape Juice inÂCyclosporine Bioavailability. , 2010, 20, 309-313.		10
161	Neonatal gastrin-releasing peptide receptor blockade reduces maternal odor preference in rats. Behavioural Brain Research, 2010, 214, 456-459.	1.2	10
162	Gastrin-Releasing Peptide Receptor Knockdown Induces Senescence in Glioblastoma Cells. Molecular Neurobiology, 2017, 54, 888-894.	1.9	10

#	Article	IF	CITATIONS
163	CXCR2 +1208 CT genotype may predict earlier clinical stage at diagnosis in patients with prostate cancer. Cytokine, 2017, 97, 193-200.	1.4	10
164	Determination of Endogenous Concentrations of Uracil and Dihydrouracil in Dried Saliva Spots by LC-MS/MS: Method Development, Validation, and Clinical Application. Therapeutic Drug Monitoring, 2019, 41, 383-390.	1.0	10
165	Outcomes and Prognostic Factors of Patients with Metastatic Colorectal Cancer Who Underwent Pulmonary Metastasectomy with Curative Intent: A Brazilian Experience. Oncologist, 2021, 26, e1581-e1588.	1.9	10
166	Resistance of HL-60 promyelocytic leukemia cells to induction of differentiation and its reversal by combination treatment. European Journal of Cancer & Clinical Oncology, 1987, 23, 739-743.	0.9	9
167	Asymptomatic Babesiosis in a Child With Hepatoblastoma. Journal of Pediatric Hematology/Oncology, 2004, 26, 213.	0.3	9
168	Quantification of the bombesin/gastrin releasing peptide antagonist RC-3095 by liquid chromatography–tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 816, 321-326.	1.2	9
169	Synergistic effect of three benzopyrans isolated from <i>Hypericum polyanthemum</i> in Uâ€373 MG glioblastoma cell line. Phytotherapy Research, 2008, 22, 1577-1580.	2.8	9
170	Effects of the Gastrin-Releasing Peptide Antagonist RC-3095 in a Rat Model of Ulcerative Colitis. Digestive Diseases and Sciences, 2010, 55, 2203-2210.	1.1	9
171	Basic Fibroblast Growth Factor Prevents the Memory Impairment Induced by Gastrin-Releasing Peptide Receptor Antagonism in Area CA1 of the Rat Hippocampus. Neurochemical Research, 2007, 32, 1381-1386.	1.6	8
172	Prevalence of vascular-endothelial growth factor, matrix metalloproteinases and tissue inhibitors of metalloproteinases in primary breast cancer. Brazilian Journal of Medical and Biological Research, 2009, 42, 979-987.	0.7	8
173	Reduced NGF Secretion by HT-29 Human Colon Cancer Cells Treated with a GRPR Antagonist. Protein and Peptide Letters, 2009, 16, 650-652.	0.4	8
174	Rescue of social behavior impairment by clozapine and alterations in the expression of neuronal receptors in a rat model of neurodevelopmental impairment induced by GRPR blockade. Journal of Neural Transmission, 2012, 119, 319-327.	1.4	8
175	Anti-EGFR therapy combined with neuromedin B receptor blockade induces the death of DAOY medulloblastoma cells. Child's Nervous System, 2013, 29, 2145-2150.	0.6	8
176	Histone deacetylase inhibition prevents the impairing effects of hippocampal gastrin-releasing peptide receptor antagonism on memory consolidation and extinction. Behavioural Brain Research, 2016, 307, 46-53.	1.2	8
177	Epidermal Growth Factor Receptor Regulation of Ewing Sarcoma Cell Function. Oncology, 2018, 94, 383-393.	0.9	8
178	Phenotype modulation of cellular UV-sensitivity. Cancer Letters, 1999, 145, 65-72.	3.2	7
179	Effects of a gastrin-releasing peptide receptor antagonist on d-amphetamine-induced oxidative stress in the rat brain. Journal of Neural Transmission, 2010, 117, 309-316.	1.4	7
180	Gastrin-Releasing Peptide Receptor Antagonist or N-acetylcysteine combined with Omeprazol Protect against Mitochondrial Complex II Inhibition in a Rat Model of Gastritis. Basic and Clinical Pharmacology and Toxicology, 2011, 108, 214-219.	1.2	7

#	Article	IF	CITATIONS
181	The Gastrin-Releasing Peptide Receptor as a Marker of Dysplastic Alterations in Cervical Epithelial Cells. Oncology, 2012, 82, 90-97.	0.9	7
182	Development, validation and clinical application of a HPLC-FL method for CYP2D6 phenotyping in South Brazilian breast cancer patients. Clinical Biochemistry, 2014, 47, 1084-1090.	0.8	7
183	The Gastrin-Releasing Peptide Receptor as a Therapeutic Target in Central Nervous System Disorders. Recent Patents on CNS Drug Discovery, 2007, 2, 125-9.	0.9	6
184	Evaluation of dried blood spots as an alternative matrix for therapeutic drug monitoring of abiraterone and delta(4)-abiraterone in prostate cancer patients. Journal of Pharmaceutical and Biomedical Analysis, 2021, 195, 113861.	1.4	6
185	Updated overall survival analysis of NAPOLI-1: Phase III study of nanoliposomal irinotecan (nal-IRI,) Tj ETQq1 1 0.7 pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy Journal of Clinical Oncology, 2016, 34, 417-417.	784314 rg 0.8	BT /Overlock 6
186	Marine-derived anticancer agents in clinical trials. Expert Opinion on Investigational Drugs, 2003, 12, 1367-1383.	1.9	6
187	Double-minute chromatin bodies in HL-60 leukemia cells sensitive and resistant to differentiation inducing agents. Cell Biology International Reports, 1987, 11, 651-655.	0.7	5
188	Clinical trials in advanced breast cancer. European Journal of Cancer & Clinical Oncology, 1987, 23, 595-597.	0.9	5
189	Malignant disease and von Willebrand factor. Lancet Oncology, The, 2001, 2, 716-717.	5.1	5
190	Cervical Cancer Screening in Porto Alegre, Brazil: Alternative Methods for Detecting Cancer Precursors in a Developing Country. Journal of Lower Genital Tract Disease, 2001, 5, 24-28.	0.9	5
191	Targeting the Bombesin/Gastrin-Releasing Peptide Receptor to Treat Sepsis. Recent Patents on Anti-infective Drug Discovery, 2007, 2, 178-181.	0.5	5
192	Expression of gastrin-releasing peptide receptor in patients with cutaneous malignant melanoma. Clinical and Experimental Dermatology, 2013, 38, n/a-n/a.	0.6	5
193	Viability of D283 medulloblastoma cells treated with a histone deacetylase inhibitor combined with bombesin receptor antagonists. Child's Nervous System, 2016, 32, 61-64.	0.6	5
194	Pharmacokinetics of brequinar sodium (NSC 368390; DUP 785) in cerebrospinal fluid. European Journal of Cancer & Clinical Oncology, 1988, 24, 1903-1904.	0.9	4
195	Laboratory and phase I studies of new cancer drugs. Current Opinion in Oncology, 1992, 4, 1065-1072.	1.1	4
196	Effects of toxic doses of glutamate on Cu?Zn and Mn/superoxide dismutases activities in human glioma cell lines. Journal of Neuro-Oncology, 2005, 71, 9-17.	1.4	4
197	RNA expression of the molecular signature genes for metastasis in colorectal cancer. Oncology Reports, 2011, 25, 1321-7.	1.2	4
198	RC-3095, a Selective Gastrin-Releasing Peptide Receptor Antagonist, Does Not Protect the Lungs in an Experimental Model of Lung Ischemia-Reperfusion Injury. BioMed Research International, 2015, 2015, 1-7.	0.9	4

#	Article	IF	CITATIONS
199	Reduced frequency of two activating KIR genes in patients with sepsis. Human Immunology, 2017, 78, 363-369.	1.2	4
200	A Placebo-Controlled Crossover Trial of Gastrin-Releasing Peptide in Childhood Autism. Clinical Neuropharmacology, 2017, 40, 108-112.	0.2	4
201	Dexamethasone and gastrin-releasing peptide receptors in human lung cells. Lung Cancer, 2004, 46, 129.	0.9	3
202	Bombesin protection against FK506 neurotoxicity. Journal of Pediatric Surgery, 2007, 42, 750.	0.8	3
203	When drugs are worth more than gold!. Lancet Oncology, The, 2007, 8, 1049-1050.	5.1	3
204	Targeting the gastrin-releasing peptide receptor pathway to treat cognitive dysfunction associated with Alzheimer's Disease. Dementia E Neuropsychologia, 2007, 1, 118-123.	0.3	3
205	Evaluation of antioxidant effect of extracts of Symphyopappus casarettoi. Fìtoterapìâ, 2007, 78, 232-234.	1.1	3
206	Phosphodiesterase-4 Inhibition and Brain Tumor Growth. Clinical Cancer Research, 2009, 15, 3238-3238.	3.2	3
207	Regulation of Eâ€cadherin expression by growth factor receptors in cancer cells. Journal of Surgical Oncology, 2011, 104, 220-221.	0.8	3
208	<scp>DEFB</scp> 1 gene 5′ untranslated region (UTR) polymorphisms are marginally involved in inflammatory bowel disease in south <scp>B</scp> razilians. International Journal of Immunogenetics, 2014, 41, 138-142.	0.8	3
209	Improvement in Symptoms of Autism Spectrum Disorder in Children With the Use of Gastrin-Releasing Peptide: An Open Trial. Clinical Neuropharmacology, 2016, 39, 215-219.	0.2	3
210	Improvement of autism spectrum disorder symptoms in three children by using gastrin-releasing peptide. Jornal De Pediatria, 2016, 92, 302-306.	0.9	3
211	A quick UPLC–MS/MS method for therapeutic drug monitoring of abiraterone and delta(4)â€∎biraterone in human plasma. Biomedical Chromatography, 2020, 34, e4947.	0.8	3
212	Targeting the Epidermal Growth Factor Receptor in Colorectal Cancer: A Potential Therapeutic Role for Gastrin-Releasing Peptide Receptor Antagonists. Oncology, 2007, 72, 160-161.	0.9	2
213	Failure of anti-EGFR therapy in p16-positive head and neck cancer. Lancet Oncology, The, 2013, 14, e436-e437.	5.1	2
214	Cellular and Clinical Pharmacokinetic/Pharmacodynamic Basis for Lack of Efficacy of 21-Day Continuous Topotecan in Patients with Untreated Advanced Adenocarcinoma of the Pancreas. Tumori, 2000, 86, 458-464.	0.6	1
215	Detecção do linfonodo sentinela em câncer da mama: comparação entre métodos. Revista Brasileira De Ginecologia E Obstetricia, 2002, 24, 479-484.	0.3	1
216	Gastrin-releasing Peptide Receptor: A Potential Target in Treatment of IBD?. Journal of Clinical Gastroenterology, 2009, 43, 288.	1.1	1

#	Article	IF	CITATIONS
217	GRPR antagonists for prostate cancer—prospects and caveats. Nature Reviews Urology, 2013, 10, 424-424.	1.9	1
218	Expression of Gastrin-releasing Peptide Receptor in Epidermoid Carcinoma of the Anal Canal. Applied Immunohistochemistry and Molecular Morphology, 2014, 22, 459-463.	0.6	1
219	KIR gene haplotype A is associated with hospital mortality in patients with sepsis. Clinical Immunology, 2019, 200, 37-38.	1.4	1
220	Resistance to differentiation affects ribo- and deoxyribonucleotide pools and sensitivity to pyrimidine metabolism antagonists in HL60 cells. Nucleosides, Nucleotides and Nucleic Acids, 2020, 39, 1369-1378.	0.4	1
221	Evolution of Truth-Telling Practices in Brazil and South America. , 2013, , 419-428.		1
222	Treatment delay and outcomes in stage IV lung cancer: The reality of a public hospital in a developing country Journal of Clinical Oncology, 2019, 37, e20709-e20709.	0.8	1
223	Anticancer drugs from nature. Medical and Pediatric Oncology, 2001, 37, 79-80.	1.0	0
224	Modulation of oxidative stress in response to gamma-radiation in human glioma cell lines. Journal of Neuro-Oncology, 2003, 62, 361-361.	1.4	0
225	The egos and the goals of reporting results. Oral Diseases, 2007, 13, 251-251.	1.5	0
226	LETTER TO THE EDITOR. Neuro-Oncology, 2009, 11, 236-237.	0.6	0
227	Lung Cancer in Brazil. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 426-431.	1.8	0
228	The rare association of leukoencephalopathy, cerebral calcifications, and cysts: case report. Journal of Epilepsy and Clinical Neurophysiology, 2010, 16, 115-117.	0.1	0
229	Updated overall survival (OS) analysis of NAPOLI-1: Phase 3 study of nanoliposomal irinotecan (nal-IRI,) Tj ETQq1 1 cancer (mPAC) previously treated with gemcitabine (gem)-based therapy Journal of Clinical Oncology, 2016, 34, 4126-4126.	l 0.78431 0.8	4 rgBT /Ove 0
230	Outcomes of chemoradiotherapy neoadjuvant for esophagus cancer in Brazil Journal of Clinical Oncology, 2016, 34, e15568-e15568.	0.8	0
231	Outcomes of chemoradiotherapy for stage III non-small-cell lung cancer in Brazil Journal of Clinical Oncology, 2016, 34, e20073-e20073.	0.8	0
232	Efficacy and safety of liposomal irinotecan (nal-IRI) + 5-fluorouracil and leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) who previously received gemcitabine (gem)-based therapy: Post-hoc analysis of the NAPOLI-1 trial Journal of Clinical Oncology, 2017, 35, 303-303.	0.8	0
233	Outcomes after the diagnosis of brain metastases in Brazilian NSCLC patients Journal of Clinical Oncology, 2017, 35, e20568-e20568.	0.8	0
234	An easy-to-handle DPD deficiency test in saliva to identify patients at high-risk for life-threatening toxicity due to fluoropyrimidine therapy Journal of Clinical Oncology, 2017, 35, e14019-e14019.	0.8	0

#	Article	IF	CITATIONS
235	Predicting 5-Fluorouracil related severe toxicity with DPD functional tests in plasma, fresh saliva and dried saliva samples Journal of Clinical Oncology, 2018, 36, e14563-e14563.	0.8	Ο
236	Outcomes and prognostic factors of patients (pts) with metastatic colorectal cancer (mCRC) who underwent pulmonary metastasectomy (PM) with curative intent Journal of Clinical Oncology, 2020, 38, 4034-4034.	0.8	0
237	Clinicopathological features and outcomes of patients with esophageal cancer undergoing neoadjuvant chemoradiation (chemoRT) in Southern Brazil: A comparison to the Worldwide Esophageal Cancer Collaboration Journal of Clinical Oncology, 2020, 38, e16535-e16535.	0.8	0